Clinical Trials
13 trialsNCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT04194554 2026-05-01
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03368729 2026-01-23
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT04926324 2025-06-29
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
Phase 1/2 Terminated
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting
NCT03425201 2024-12-31
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 1/2 Completed
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT03644342 2024-09-03
NIVIX
Baylor College of Medicine
Phase 1/2 Terminated
NCT06258018 2024-08-30
ONC-2022-001
Istituto Clinico Humanitas
Phase 1/2 Not yet recruiting
NCT02354131 2022-08-30
AVANOVA
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 1/2 Completed